101 related articles for article (PubMed ID: 16733218)
1. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
2. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
Kim EK; Kim KA; Lee CY; Shim HS
PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
Kwak EL; Jankowski J; Thayer SP; Lauwers GY; Brannigan BW; Harris PL; Okimoto RA; Haserlat SM; Driscoll DR; Ferry D; Muir B; Settleman J; Fuchs CS; Kulke MH; Ryan DP; Clark JW; Sgroi DC; Haber DA; Bell DW
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4283-7. PubMed ID: 16857803
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies.
Xiong Y; Bai Y; Leong N; Laughlin TS; Rothberg PG; Xu H; Nong L; Zhao J; Dong Y; Li T
Diagn Pathol; 2013 Feb; 8():27. PubMed ID: 23419122
[TBL] [Abstract][Full Text] [Related]
5. Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma.
Shi Z; Zheng X; Shi R; Song C; Yang R; Zhang Q; Wang X; Lu J; Yu Y; Liu Q; Jiang T
Sci Rep; 2017 Mar; 7(1):364. PubMed ID: 28336963
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.
Jang J; Son J; Park E; Kosaka T; Saxon JA; De Clercq DJH; Choi HG; Tanizaki J; Eck MJ; Jänne PA; Gray NS
Angew Chem Int Ed Engl; 2018 Sep; 57(36):11629-11633. PubMed ID: 29978938
[TBL] [Abstract][Full Text] [Related]
7. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.
Reis-Filho JS; Milanezi F; Carvalho S; Simpson PT; Steele D; Savage K; Lambros MB; Pereira EM; Nesland JM; Lakhani SR; Schmitt FC
Breast Cancer Res; 2005; 7(6):R1028-35. PubMed ID: 16280056
[TBL] [Abstract][Full Text] [Related]
8. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.
Sun M; Behrens C; Feng L; Ozburn N; Tang X; Yin G; Komaki R; Varella-Garcia M; Hong WK; Aldape KD; Wistuba II
Clin Cancer Res; 2009 Aug; 15(15):4829-37. PubMed ID: 19622585
[TBL] [Abstract][Full Text] [Related]
9. The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.
Zhang MS; Yeh YC; Huang HN; Lin LW; Huang YL; Wang LC; Yao LJ; Hung TC; Tseng YF; Lee YH; Liao WY; Shih JY; Hsieh MS
PLoS One; 2024; 19(4):e0301120. PubMed ID: 38687753
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases.
Udart M; Utikal J; Krähn GM; Peter RU
Neoplasia; 2001; 3(3):245-54. PubMed ID: 11494118
[TBL] [Abstract][Full Text] [Related]
11. Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China.
Yang L; Che Y; Guo L; Zheng B; Wang B; Yang Z; Zhu Y; Li J
Thorac Cancer; 2018 Apr; 9(4):439-444. PubMed ID: 29400000
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.
Weiss GA; Rossi MR; Khushalani NI; Lo K; Gibbs JF; Bharthuar A; Cowell JK; Iyer R
J Gastrointest Oncol; 2013 Mar; 4(1):20-9. PubMed ID: 23450128
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine.
Lee Y; Lee B; Choi YL; Kang DW; Han J
Mod Pathol; 2024 Apr; 37(6):100490. PubMed ID: 38588887
[TBL] [Abstract][Full Text] [Related]
14. Adenocarcinoma of the Lung with Miliary Metastases and Primary Resistance Exon 20 Mutations.
Hsu F
Cureus; 2018 Oct; 10(10):e3533. PubMed ID: 30648067
[TBL] [Abstract][Full Text] [Related]
15. Activating HER2 mutations as emerging targets in multiple solid cancers.
Connell CM; Doherty GJ
ESMO Open; 2017; 2(5):e000279. PubMed ID: 29209536
[TBL] [Abstract][Full Text] [Related]
16. Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
Fromhage G; Obermayr E; Bednarz-Knoll N; Van Gorp T; Welsch E; Polterauer S; Braicu EI; Mahner S; Sehouli J; Vergote I; Concin N; Kurtz S; Steinbiss S; Torge A; Zeillinger R; Wölber L; Brandt B
Int J Cancer; 2024 May; ():. PubMed ID: 38709956
[TBL] [Abstract][Full Text] [Related]
17. Multiple primary lung adenocarcinomas pre-operatively diagnosed by discordant epidermal growth factor receptor mutations.
Katayama Y; Kawai S; Miyagawa-Hayashino A; Takemura Y
Respirol Case Rep; 2019 Aug; 7(6):e00434. PubMed ID: 31139414
[TBL] [Abstract][Full Text] [Related]
18. Triple-Negative Metaplastic Breast Carcinoma: Association of Epidermal Growth Factor Receptor Expression With Prognostic Parameters and Clinical Outcome.
Munawar S; Haider R; Ali SM; Yaqeen SR; Islam S; Asghar IA; Afzal A; Zia S; Irfan M; Hashmi AA
Cureus; 2021 May; 13(5):e15006. PubMed ID: 34150374
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Garon EB; Siegfried JM; Stabile LP; Young PA; Marquez-Garban DC; Park DJ; Patel R; Hu EH; Sadeghi S; Parikh RJ; Reckamp KL; Adams B; Elashoff RM; Elashoff D; Grogan T; Wang HJ; Dacic S; Brennan M; Valdes Y; Davenport S; Dubinett SM; Press MF; Slamon DJ; Pietras RJ
Lung Cancer; 2018 Sep; 123():91-98. PubMed ID: 30089602
[TBL] [Abstract][Full Text] [Related]
20. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
